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Abstract
The omnigenic model of complex disease stipulates that the majority of the heritability will be explained by the effects of
common variation on genes in the periphery of core disease pathways. Rare variant associations, expected to explain far less
of the heritability, may be enriched in core disease genes and thus will be instrumental in the understanding of complex
disease pathogenesis and their potential therapeutic targets. Here, using complementary whole-exome sequencing, high-
density imputation, and in vitro cellular assays, we identify candidate core genes in the pathogenesis of systemic lupus eryth-
ematosus (SLE). Using extreme-phenotype sampling, we sequenced the exomes of 30 SLE parent-affected-offspring trios and
identified 14 genes with missense de novo mutations (DNM), none of which are within the>80 SLE susceptibility loci impli-
cated through genome-wide association studies. In a follow-up cohort of 10, 995 individuals of matched European ancestry,
we imputed genotype data to the density of the combined UK10K-1000 genomes Phase III reference panel across the 14 candi-
date genes. Gene-level analyses indicate three functional candidates: DNMT3A, PRKCD, and C1QTNF4. We identify a burden of
rare variants across PRKCD associated with SLE risk (P¼0.0028), and across DNMT3A associated with two severe disease prog-
nosis sub-phenotypes (P¼0.0005 and P¼0.0033). We further characterise the TNF-dependent functions of the third candidate
gene C1QTNF4 on NF-jB activation and apoptosis, which are inhibited by the p.His198Gln DNM. Our results identify three
novel genes in SLE susceptibility and support extreme-phenotype sampling and DNM gene discovery to aid the search for
core disease genes implicated through rare variation.
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Introduction
Considerable progress has been made in elucidating the genetic
basis of complex diseases. The vast majority of identified disease-
associated genetic polymorphisms are common in the population
and the risk alleles impart a modest individual increment to the
likelihood of developing disease. Although large-scale genome-
wide association studies (GWAS) have so far explained less of the
heritability than originally predicted (1), much of the ‘missing her-
itability’ is expected to be accounted for by common variants with
effect sizes below the genome-wide significance threshold (2).
However, under the newly proposed omnigenic model of complex
traits, the majority of associated common variants—both identi-
fied and unidentified—will primarily be found in periphery genes
expressed in relevant cell types but not necessarily biologically rel-
evant to disease (3).
In contrast, the role of rare variants in complex disease is
largely unknown and often dismissed. A recent study, however,
with an extremely large sample size, identified rare and low fre-
quency variants contributing to the genetic variance of adult
human height (4)—a polygenic trait with a genetic architecture
similar to that of complex diseases (5)—suggesting previous com-
plex disease studies with seemingly large sample sizes were per-
haps still insufficiently powered to detect rare variant associations
(6). Furthermore, studies of rare variants typically find gene sets
enriched in biologically relevant functions/pathways (3,7,8).
Therefore, although estimated to explain less of the heritable dis-
ease risk at a population level than common variants, identifying
rare and low frequency variants is of paramount importance to
understanding disease pathogenesis as they are likely to implicate
biologically relevant core genes (3). The underrepresentation of rare
variant associations within GWAS loci supports the theory that a
discrete set of genes will be implicated through rare variants (9).
Exome-wide searches, which provides a highly enriched source
of potential disease-causing mutations (10), have revealed limited
numbers of rare variation associated with complex diseases. Even
though greater statistical power is achieved by gene-level analyses
whereby aggregated variants are tested for an allelic burden of col-
lective rare variation, widely used gene-based association tests
have been shown to lack power at the exome-wide level (11).
Coupled with the insufficient sample sizes currently available in
the study of most complex diseases, hypothesis-free searches for
core genes with rare variant associations are unlikely to be fruitful.
Our strategy to address this problem in autoimmune disease
SLE (SLE; MIM 152700), is outlined here and summarised in
Figure 1. Using a discovery cohort of 30 unrelated SLE cases with
a severe disease (young age of onset and clinical features associ-
ated with poorer outcome), we hypothesized that these individu-
als would exhibit unique mutation events in their protein-coding
DNA that may predispose to disease risk. We undertook whole-
exome sequencing (WES) in 30 family trios (both parents and
affected offspring) and scrutinized the data for non-inherited de
novo mutations (DNM) in the individual with SLE to identify a
group of candidate genes for an independent follow-up rare var-
iant analysis. This method allowed the identification of novel loci
harbouring disease risk through collective rare variation, and
emphasises the value of phenotypic extremes in the search for
core genes in multifactorial disorders (12).
Results
Identification of DNM in extreme-phenotype SLE cases
We screened for DNM by WES of 30 family trios with an affected
offspring with more severe SLE (Supplementary Material, Fig. S1). A
total of 584 798 variants (20X), including single nucleotide var-
iants and indels, were identified in the 30 affected probands. Using
three bioinformatic tools and employing conservative parameters,
17 putative missense DNM were identified across 17 genes
(Supplementary Material, Table S1, Fig. S2). We also analysed the
SLE proband WES data alone, without the unaffected parents. This
revealed 1194 non-silent, heterozygous, rare variants in 1, 067
genes distributed across the genome, which would make prioriti-
zation for downstream analysis a difficult task, highlighting the
benefit of parent-offspring trio sequencing (Supplementary
Material, Fig. S3). Sanger sequencing confirmed 14 true positive
non-silent DNM (Table 1; Supplementary Material, Table S2),
present in the SLE proband but absent in both parents and any
unaffected siblings, in 11 of the 30 probands (36.7%) for further
analysis. No DNM was found in any of the>80 known SLE-
associated genes. Of the three false positive DNM (11.7%;
Supplementary Material, Table S1) one, within LAMC2, is likely a
result of germline mosaicism because, although not observed in
either parent, it is observed in an unaffected sibling in addition to
the SLE proband (13), and the other two variants are within
KRTAP10–2 and KLRC1—both members of highly homologous gene
families. Such sequence identity may have caused false positive
identification of DNM in the WES analysis and suggests our NGS
error-prone genes (NEPG) filter, which removes loci known to be
problematic for genome mapping during NGS analyses, should
have been more conservative. Indeed the KRLC1 p.Ile225Met mis-
sense variant appears to be a polymorphic Paralogous Sequence
Variant (PSV)—the paralogous variant being p.Met223Ile in KLRC2.
Variant- and gene-level functional characterization of
DNM
In order to best predict the phenotypic effect of the 14 DNM, we
used both variant-level and gene-level metrics (14). We used the
ExAC database (15) and Combined Annotation Dependent
Depletion (CADD) scores (16) to characterise the frequency and
predicted functional effects, respectively, of the variants. Five of
the 14 DNM—found in MICALL1, LRP1, PNPLA1, PLD1, and
GFTP2—have been observed, at very rare frequencies, in the 60
000 exomes documented in ExAC (Table 1). All five mutations
are CpG transitions and therefore likely to be identity-by-state,
reflecting the higher mutability rate of these sites. Within the
mutation set, five (35.7%)—found in DNMT3A, PRKCD, MICALL1,
LRP1, and PNPLA1—have CADD Phred scores>30, placing them
in the top 0.1% of possible damaging mutations in the human
genome (Table 1). We further explored the function, expression
(BioGPS), existing autoimmunity associations (ImmunoBase),
and gene-level constraint against missense mutations (ExAC),
of the DNM genes to build a profile of a priori evidence of a role
in SLE pathogenesis. None of the candidate genes have been
previously associated with SLE through GWAS in any popula-
tion (17). We also identify candidate genes through known/pre-
dicted function and expression profiles (C1QTNF4, SRRM2,
HMSD), and four genes (PRKCD, DNMT3A, C1QTNF4 and LRP1)
with a significant (Z> 3.09) constraint against missense variants
(Table 2). However, across the entire gene set, there was no dif-
ference in the median Z-score (0.50) compared with the median
Z-score across all genes in ExAC (0.51).
PRKCD and DNMT3A are associated with SLE through
collective rare variation
Although the variant- and gene-level metric analyses suggested
intriguing functional candidates, we took a comprehensive
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approach and tested each locus for an allelic burden of rare var-
iation. We hypothesized that, while some observed DNM were
random background variation as present in the exome of every
individual regardless of disease status (18), others may be
reflecting a hitherto unknown gene contributing to SLE risk, and
this may be shown through rare variant burden. Therefore, gen-
otype data were imputed (Supplementary Material, Figs S6 and
S7) to the density of the combined UK10K and 1000 genomes
Phase III reference panel (UK10K-1000GP3) across all 14 DNM
genes in a follow-up cohort of 10 995 individuals of matched
European ancestry previously genotyped on the Illumina
HumanOmni1 BeadChip (19). Under the hypothesis that rare
variants at these loci would be causal and not protective, we
employed a one-tailed collapsing burden test (20) to survey
each of the 14 genes for an excess of aggregated rare (MAF< 1%)
exonic variants in SLE cases compared with healthy controls.
We identify an association of PRKCD rare variants with SLE
(Supplementary Material, Table S3; P¼ 0.0028; ncases¼4036). In
sub-phenotype analyses, we identify collective rare exonic
variants in DNMT3A associated with both anti-dsDNA
(Supplementary Material, Table S3; P¼ 0.0005; ncases¼1261) and
renal involvement with hypocomplementemia (Supplementary
Material, Table S3; P¼ 0.0033; ncases¼186), both of which are
markers of more severe disease. We also collapsed all exons
from the 14 genes together to test for an overall burden of rare
variants across these loci. These analyses revealed no excess of
rare exonic variants across the grouped genes, reflecting the
hypothesis that some/most genes will not be relevant to disease
status because the observed DNM are random background var-
iation only. These data reflect the results of our gene-level con-
straint metric, in which the aggregated gene set do not have a
significant mutation constraint. Together, these results suggest
further prioritization based on gene-level metrics would not
have resulted in true positive associations being excluded from
analyses.
Implication of C1QTNF4 in SLE through functional effect
of DNM p.His198Gln
Although no rare variant association was found at the novel
candidate gene C1QTNF4, its potential role in disease is sup-
ported by gene-level metrics—it is a compelling functional
Figure 1. Overview of study. De novo mutations (DNM) in a discovery cohort revealed candidate genes for imputation-based rare variant burden testing using a follow-
up cohort. Independent functional analyses demonstrate the functional effects of one DNM in a candidate gene.
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candidate and one of four genes constrained against missense
variants (ExAC gene-level constraints Z¼ 3.17, Table 2).
Although gene coding length does not correlate with missense
constraint scores (15), the small (<1Kb) coding sequence of this
candidate gene may have contributed to insufficient power to
detect a rare variant association in the burden testing. On the
variant-level, the DNM in C1QTNF4 generates a p.His198Gln
sequence change with a modest CADD score of 12.3 (Table 1).
Although useful in the absence of suitable functional assays,
the sensitivity of bioinformatic prediction tools is known to be
suboptimal. Where functional assays are available, previous
studies have also demonstrated functional effects of variants
predicted to be tolerated/benign (21). We therefore pursued a
functional analysis of the p.His198Gln DNM detected in the
C1QTNF4 gene as an alternative method to add support for its
potential role in disease. Although its function is rather poorly
understood, the protein product, C1QTNF4 (CTRP4) is secreted
and may act as a cytokine, as it has homology with TNF and the
complement component C1q (Fig. 2). C1QTNF4 has been shown
to influence NF-jB activation (22), a pathway known to be impli-
cated in SLE pathogenesis, therefore we looked for an effect of
the p.His198Gln mutation on NF-jB production. Using a
HEK293-NF-jB reporter cell line, we showed that C1QTNF4
p.His198Gln mutant protein was expressed and that it inhibited
the NF-jB activation generated by exposure to TNF (Fig. 2).
Furthermore, we showed that the fibroblast L929 cell line, which
is sensitive to TNF-induced cell death, was rescued by exposure
to C1QTNF4 p.His198Gln, but not by wild type C1QTNF4. Thus,
the mutant form of C1QTNF4 appears to inhibit some of the
actions of TNF (23–25).
DNM genes do not harbour common variant
associations
We next tested for additional common variant associations at
these 14 loci using the high-density UK10K-1000GP3 imputed
data. No significant association at any locus was observed with
overall risk in a case-control comparison (ncases¼4036), nor with
anti-dsDNA (ncases¼1261) or renal involvement with hypocom-
plementemia (ncases¼186) sub-phenotypes (Supplementary
Material, Table S4). The lack of an associated common variant
within PRKCD and DNMT3A supports the hypothesis that dis-
crete gene sets will be identified through rare and common var-
iant associations, with the former expecting to be enriched for
core disease genes (3).
Discussion
To fully understand the pathogenesis of complex diseases we
must analyse the full frequency spectrum of genetic variants
(4). The study of rare variants associated with disease is of para-
mount importance to the discovery of core genes that have the
potential to be therapeutic targets (12). Our data support the
omnigenic hypothesis that rare genetic risk may be found in a
discrete set of non-canonical susceptibility genes, as we report
an association of collective rare variation across PRKCD and
DNMT3A, and found no evidence of an association with com-
mon variants across these loci. This, to the best of our knowl-
edge, is the first WES study in polygenic cases of autoimmune
disease to use DNM discovery to identify candidate genes for
rare variant analyses. Furthermore, our study supports the
Table 1. De novo mutations in SLE probands with extreme phenotypes
Family Mutation (chr:
position ref: alt)
Gene Gene description Exon Amino acid MAF in
ExACa
CADD
Phred
Mutation
typeb
SLE0751 22: 38336799 C: T MICALL1 MICAL-like 1 16 Arg852Cys 1.5  104 35 Ti CpG
SLE0496 3: 53223122 G: A PRKCD protein kinase C, delta 16 Gly535Arg – 34 Ti CpG
SLE0679 12: 57588368 C: T LRP1 Low-density lipoprotein
receptor-related protein 1
50 Arg2693Cys 8.3  104 34 Ti CpG
SLE0592 6: 36260896 G: A PNPLA1 patatin-like phospholipase
domain containing 1
3 Arg166His 5.8  105 33 Ti CpG
SLE0296 2: 25457236 G: A DNMT3A DNA (cytosine-5-)-methyl-
transferase 3 alpha
19 Ala695Val – 32 Ti CpG
SLE0571 4: 79512728 G: T ANXA3 annexin A3 7 Ser145Ile – 25.2 Tv
SLE0679 3: 171431716 G: A PLD1 phospholipase D1, phos-
phatidylcholine-specific
9 Thr293Met 5.8  105 25.1 Ti CpG
SLE0411 5: 179743769 C: T GFPT2 glutamine-fructose-6-phos-
phate transaminase 2
12 Val383Met 2.6  105 23.4 Ti CpG
SLE0679 7: 138968784 C: A UBN2 ubinuclein 2 15 Pro1045Thr – 18.46 Tv
SLE0080 16: 2812426 C: T SRRM2 serine/arginine repetitive
matrix 2
11 Arg633Cys – 14.32 Ti CpG
SLE0852 11: 47611769 G: C C1QTNF4 C1q and tumor necrosis fac-
tor related protein 4
2 His198Gln – 12.29 Tv
SLE0321 18: 61621642 G: A HMSD histocompatibility (minor)
serpin domain
containing
3 Ala25Thr – 9.732 Ti
SLE0390 12: 32369376 G: C BICD1 bicaudal D homolog 1
(Drosophila)
2 Val137Leu – 8.673 Tv
SLE0321 1: 35251125 C: G GJB3 gap junction protein, beta 3 2 Asp254Glu – 0.002 Tv
The mutations are ordered by level of severity, from most to least, predicted by CADD score.
aFrequencies are presented from all 61 468 multiethnic individuals in ExAC because the de novo mutations observed in ExAC are likely to be identity-by-state not iden-
tity-by-descent.
bTv¼Transversion; Ti¼Transition; Ti CpG¼Transition within a CpG dinucleotide.
424 | Human Molecular Genetics, 2018, Vol. 27, No. 3
importance of phenotypic extremes in elucidating the genetic
basis of multifactorial disorders (26).
Searching GWAS-identified canonical disease susceptibility
genes for additional rare variant risk has not been fruitful.
Although there are examples—and perhaps more to discover—
of canonical disease genes harbouring both common and rare
risk alleles (27), the vast majority of such loci do not. Indeed the
common variant associated loci which have also been shown to
harbour rare coding variant risk are often those distinct minor-
ity of loci where the common polymorphisms are non-silent
coding variants [e.g. NCF2 (9)]. It is important to note, however,
that the separation of periphery and core genes may not neces-
sarily be binary (3).
DNMT3A and PRKCD, although hitherto not associated with
polygenic SLE, are known autoimmunity susceptibility loci;
DNMT3A is associated with Crohn’s disease (CD) (28) and PRKCD
is associated with both CD and ulcerative colitis (UC) (29). The
notion that a locus could harbour common variants contribu-
ting to one autoimmune disease and rare variants contributing
to another is intriguing, and could provide further hypothesis-
driven searches in the hunt for disease-specific core genes.
A functional missense variant p.G510S (c.G1528A) in PRKCD
has previously been reported in a consanguineous family with
monogenic SLE (30). It was demonstrated that the PRKCD-
encoded protein, PRCd, was essential in the regulation of B cell
tolerance and affected family members with the homozygous
mutation had increased numbers of immature B cells. Our study
implicates the role of rare variants in PRKCD in the broader con-
text of SLE susceptibility, beyond a monogenic recessive disease
model. Indeed the analysis of rare and low frequency variants
contributing to human height found significant overlap with
genes mutated in monogenic growth disorders (4). Furthermore,
PRKCB, another member of the protein kinase C gene family,
has been implicated in SLE risk (31).
DNMT3A, a DNA methyltransferase, is a very intriguing can-
didate gene for SLE as altered patterns of DNA methylation are
reported in autoimmune diseases (32), and hypomethylation of
apoptotic DNA has been reported to induce autoantibody pro-
duction in SLE (33). DNA methylation changes are also associ-
ated with monozygotic twin discordance in SLE (34). A
candidate gene study previously reported a trend of association
between the common DNMT3A intronic SNP rs1550117
(MAF7%) and SLE in a European cohort (35). Our analysis did
not replicate this finding (P¼ 0.23) and found no evidence of a
common variant association at this locus. Instead, we find an
association of collective rare variants and SLE sub-phenotypes
and emphasises the importance of deep phenotyping and the
potential role of rare variants in specific sub-phenotype, or
indeed autoimmune, manifestations. Despite progress with
diagnosis and treatment, particular SLE sub-phenotypes—
including those used in this study—are still associated with
reduced life expectancy. Therefore, elucidating the specific
underlying genetic risk is of paramount importance.
Through two in vitro assays, we demonstrated the functional
effect of a DNM, p.His198Gln in candidate gene C1QTNF4,
despite this mutation being predicted to be of little functional
importance across variant-level prediction tools. We showed
the mutated protein product of C1QTNF4, C1QTNF4, inhibits
some TNF-mediated cellular responses, including activation of
NF-jB and TNF-induced apoptosis. The role of TNF in SLE is
complex and incompletely understood, although, in this con-
text, it is noteworthy that TNF inhibition may promote antinu-
clear autoimmunity (24). Gene-level metrics for C1QTNF4 were
supportive of a role in disease and our result support the impor-
tance of combined gene- and variant-level metrics, and the dan-
gers of relying heavily on variant-level metrics alone, when
interpreting the potential role of mutations (14). C1QTNF6 is a
known susceptibility locus for Type 1 Diabetes and is implicated
in Rheumatoid Arthritis (36,37), and a suggestive association
with SLE has recently been described in a transancestral
Immunochip analysis (38). Together, these data suggest a
Table 2. Evidence for role of de novo mutation gene in autoimmunity
Gene Functional candidatea Association
with SLEb
Associations
with other AIDb
Immune cell
type with highest
expressionc
Missense
constraintd
PRKCD B cell signaling and self-antigen induced
B cell tolerance induction
Monogenic
forms30
IBD, UC, CD28 Dendritic 3.75*
DNMT3A DNA methyltransferase Candidate
gene study35
CD29 – 4.31*
C1QTNF4 Pro-inflammatory cytokine – – CD34þ 3.17*
SRRM2 Spliceosome-associated pre-mRNA splicing – – CD8þ No data
LRP1 Endo/Phagocytosis of apoptotic cells – – – 10.60*
HMSD Minor histocompatibility antigen – – n/a 0.25
UBN2 DNA binding – – – 0.01
ANXA3 – – RA17 – 0.37
PLD1 – – – Lymphoblasts 0.73
PNPLA1 – – – – 0.27
GFPT2 – – – – 1.59
BICD1 – – – – 2.12
GJB3 – – – – 0.81
MICALL1 – – – – 0.50
Genes appear in descending order of supporting evidence. UC¼ulcerative colitis, CD¼Crohn’s Disease, IBD¼ inflammatory bowel disease, RA¼Rheumatoid Arthritis.
aSee Supplementary Material, Table S5.
bSee Supplementary Material, Table S6.
cSee Supplementary Material, Figure S4. Data from BioGPS. If gene expression is highest in immune cells compared with all other cells, the immune cell type with high-
est expression is listed.
dGene-wise ExAC Constraint Z-scores. Genes with significant restraint against missense variants are highlighted with an asterisk.
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potential role of the hitherto understudied C1QTNF superfamily
of genes in autoimmunity.
Although our study allowed a comprehensive approach to
test all DNM genes for allelic burden of rare variants, our results
show that filtering based on gene- or variant-level metrics
would not have resulted in true associations of DNMT3A and
PRKCD being missed. When larger datasets require further pri-
oritization of genes, we suggest both variant- and gene-level
metrics are used.
Each human—regardless of the disease status—is estimated
to have one DNM in their exome (18). The simple presence of a
provisionally functional DNM in a proband is therefore not suffi-
cient evidence that it contributes to disease risk. A major chal-
lenge of WES studies, therefore, is how to differentiate between
variants truly important to disease and background variation
(39). In light of recent studies which have demonstrated the lim-
itations of large-scale exome-wide case-control studies in
detecting rare variant associations (6,40), despite such associa-
tions being found when no limitation on sample size exists (4),
our results support extreme-phenotype sampling and DNM dis-
covery to aid a hypothesis-driven search for rare variant associ-
ations with complex diseases, in the hunt to determine core
disease genes.
Materials and Methods
Selection of trios for sequencing
SLE patients of European ancestry—as determined by genome-
wide genotyping as part of a GWAS (19)—were selected from the
UK SLE genetic repository assembled in the Vyse laboratory on
the following criteria: age of onset of SLE< 25 years (median age
21 years); more marked disease phenotype as shown by either
evidence for renal involvement as per standard classification
Figure 2. Structural and functional characterization of C1QTNF4 p.His198Gln substitution. (A) Domain organization of human C1QTNF4, showing signal peptide (yel-
low), first C1q domain (green), second C1q domain (blue) and linker peptides (grey). Arrow highlights substitution site. (B) 3D structure prediction of C1QTNF4 and
C1QTNF4 p.His198Gln using Phyre2 (47). Ribbons show the interaction between the positively charged Histidine 198 and Proline 196 lost in C1QTNF4 p.His198Gln due to
the substitution of Histidine with Glutamine. (C) Immunoblot demonstrating that p.His198Gln does not affect secretion of C1QTNF4 in HEK293 supernatants. (D) Size
exclusion chromatography profile showing no difference in oligomerization between supernatant containing C1QTNF4 (blue) and C1QTNF4 p.His198Gln (red).
(E) Luciferase assay in HEK293-NF-jB reporter cell line showing that C1QTNF4 p.His198Gln inhibits NF-jB activation in response to 4 h stimulation with 5 ng/ml TNFa.
Error bars represent standard error of the mean. (F) Inhibition of L929 induced cell death by C1QTNF4 p.His198Gln after 24h of stimulation with 0.45 ng/ml TNFa in pres-
ence of Actinomycin 1 lg/ml. EV¼empty vector.
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criteria and/or the presence of hypocomplementemia and anti-
dsDNA autoantibodies; and DNA available from both unaffected
parents. The 30 trios (90 individuals) were exome sequenced, as
described in SI Methods. Ethical approval for the research was
granted by the NRES Committee London (12/LO/1273 and 06/
MRE02/9).
DNM calling
Three bioinformatics tools with conservative parameters were
used for DNM screening: BCFtools (41), DeNovoGear (42) and
DeNovoCheck (43). A detailed description of the methods
applied can be found in SI Methods. Briefly, 454 variants were
identified with BCFtools and DeNovoGear and eight additional
variants were identified by DeNovoCheck and validated by IGV,
resulting in a total of 462 variants, which map to 257 genes. The
variants were next filtered sequentially filtered (Supplementary
Material, Fig. S2): (A) Removal of NEPG; (B) Fulfil a Het: Ref: Ref
for Child: Father: Mother de novo pattern of inheritance and fur-
ther selected variants that did not contain any trace of alternate
allele in any of the parents; (C) Non-silent variant annotation.
This process resulted in a total of 17 variants in 17 genes
(Supplementary Material, Table S1).
Analysis of WES in cases only
584, 798 variants with20X coverage depth and within Gencode
capture regions were identified in the analysis of 30 SLE pro-
bands only. Stringent filters were applied for variant refinement,
described in full in SI Methods, resulting in 1194 variants in 1067
genes (Supplementary Material, Fig. S3).
Sanger sequencing confirmation
Primers were designed using Primer 3. 10ng of DNA from SLE
probands, any unaffected siblings and both parents was ampli-
fied with Hot Start Taq polymerase. PCR products were first
purified with EXO-SAP before BigDye labelling in a linear PCR
and sequenced on an ABI 3300XL. Primers and PCR conditions
available on request. The reads were analysed using Chromas
Lite (v.2.1.1).
Imputation
Illumina HumanOmni1 BeadChip genotype data from 6995
controls and 4036 SLE patients of matched European ancestry
were used, which had undergone quality control as previously
described including Principal Component Analysis (PCA) to
account for population structure (19). The UK10K (REL-2012–06-
02) plus 1000 Genomes Project Phase3 data (release 20131101.v5)
merged reference panel (UK10K-1000GP3) was accessed through
the European Genome-phenome Archive (EGAD00001000776).
The genotype data were imputed using the UK10K-1000GP3
reference panel across the coding regions of the 14 DNM genes
plus a 2Mb flanking region. To increase the accuracy of imputed
genotype calls, a full imputation without pre-phasing was con-
ducted using IMPUTE2 (44,45). Imputed genotypes were filtered
for confidence using an info score (IMPUTE2) threshold of 0.3
(Supplementary Material, Figs S6 and S7). The most likely geno-
type from IMPUTE2 was taken if its probability was> 0.5. If the
probability fell below this threshold, it was set as missing.
Variants with>10% missing genotype calls were removed for
further analysis. All individuals had<8% missing genotype
data.
Rare variant burden tests
Imputed data were filtered, using Plink v1.9, to include only var-
iants mapping to coding exons of hg19 RefSeq transcripts. Plink/
SEQv1.0 (20) was used to run gene-wise one-tailed burden test-
ing with a MAF< 1% threshold. A 5% false discovery rate was
used for multiple testing correction for 14 genes.
Common variant association tests
SNPTEST 2.5.2 (46) was used to test for associated variants with
MAF> 1% across the region spanning the encoded gene. The
first four covariates from the original GWAS were included (19).
Bonferroni correction was used for 3000 tests across the loci
(q¼ 1.66E-5).
Plasmids
Myc-Flag-tagged C1QTNF4 on the pCMV6 vector and the empty
pCMV6 vector were used (OriGene). The mutant pCMV6-
C1QTNF4 C594G (p.His198Gln) was generated by site-directed
mutagenesis (Quikchange II XL; Stratagene) according the man-
ufacturer’s instructions: mutagenic primer: 5’-GCGAGTG
GTTGCTGCCGCGGCCC-3’ (Sigma-Aldrich). The plasmids pro-
duction was carried out in XL10-Gold Ultracompetent cells, iso-
lated and purified using EndoFree Maxi Prep kit (Qiagen) and
plasmid ORFs were confirmed by full Sanger sequencing (GATC-
Biotech). The expression and secretion of the flagged proteins
was confirmed by western blot on cell lysates and supernatants
with monoclonal anti-FLAG antibody (clone M2; Sigma-Aldrich).
Luciferase assays and TNF-induced programmed cell
death
GloResponse NF-jB-RE-luc2P HEK293 cell line (Promega) and
TNF-sensitive L929 fibrosarcoma cell line (ATCC) were cultured
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and 1% Penicillin/
Streptomycin at 37 C, 5% CO2. HEK293 were seeded 24 h before
transfection in antibiotic free DMEM in 96 wells plate (2 104
cells/well), transfected with either C1QTNF4, C1QTNF4 C594G or
Empty Vector via Fugene HD (Promega). Forty eight hours after
transfection the cell were left unstimulated or stimulated with
TNFa 5 ng/ml (PeproTech) for 4 h. Luciferase activity was
assayed by One-Glo (Promega) on Berthold Orion luminometer,
the values were normalized to cell viability measured by
CellTiter Glo (Promega). L929 were challenged with TNFa 0.45
ng/ml and Actinomycin D 1 lg/ml (R&D) for 24 h in presence of
C1QTNF4 or C1QTNF4 p.His198Gln containing media, cell viabil-
ity was measured by CellTiter Glo.
Size exclusion chromatography
Supernatants (750 ml) of HEK293 producing C1QTNF4 or
C1QTNF4 p.His198Gln were buffer exchanged in PBS on Zeba
Spin Desalting Columns (Thermo Fisher) and 0.5 ml loaded on
an AKTA FPLC with a Superdex 200 10/300 GL column (GE
Healthcare). Absorbance was normalized to the maximum peak
of each sample.
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